John Lunger Net Worth

The estimated Net Worth of John Lunger is at least $224 Tausend dollars as of 16 January 2024. Mr. Lunger owns over 22,795 units of Adaptimmune Therapeutics Plc stock worth over $20,536 and over the last 5 years he sold ADAP stock worth over $203,373. In addition, he makes $0 as Chief Patient Supply Officer at Adaptimmune Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lunger ADAP stock SEC Form 4 insiders trading

John has made over 19 trades of the Adaptimmune Therapeutics Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 22,795 units of ADAP stock worth $15,957 on 16 January 2024.

The largest trade he's ever made was selling 22,795 units of Adaptimmune Therapeutics Plc stock on 16 January 2024 worth over $15,957. On average, John trades about 3,198 units every 57 days since 2019. As of 16 January 2024 he still owns at least 19,015 units of Adaptimmune Therapeutics Plc stock.

You can see the complete history of Mr. Lunger stock trades at the bottom of the page.

John Lunger biography

John Lunger serves as Chief Patient Supply Officer of the Company. Prior to joining Adaptimmune in 2017, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals, where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack's first commercial product. Earlier in his career, John held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. John's previous roles include serving as a nuclear trained officer on a U.S. Navy submarine, strategic supply chain consulting with Accenture, and business development with a start-up procurement services company. He holds a Bachelor of Science degree (with distinction) in Ocean Engineering from the U.S. Naval Academy and an MBA in economics and operations management from the University of Chicago's Booth School of Business.

How old is John Lunger?

John Lunger is 51, he's been the Chief Patient Supply Officer of Adaptimmune Therapeutics Plc since 2019. There are 14 older and 4 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.

What's John Lunger's mailing address?

John's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.

Insiders trading at Adaptimmune Therapeutics Plc

Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.

What does Adaptimmune Therapeutics Plc do?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Complete history of Mr. Lunger stock trades at Adaptimmune Therapeutics Plc und Genocea Biosciences Inc

Adaptimmune Therapeutics Plc executives and stock owners

Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include:

• James Noble,
  Non-Executive Director
• Adrian Rawcliffe,
  Chief Executive Officer, Director
• William Bertrand,
  Chief Operating Officer
• Helen Tayton-Martin,
  Chief Business Officer
• Adrian G. Rawcliffe,
  CEO, Principal Accounting Officer & Director
• Dr. Helen Katrina Tayton-Martin MBA, Ph.D.,
  Co-Founder & Chief Bus. Officer
• William C. Bertrand Jr.,
  Chief Operating Officer
• Gavin Hilary James Wood BA (Hons), ACA,
  Chief Financial Officer
• David Mott,
  Non-Executive Independent Chairman of the Board
• Tal Zvi Zaks,
  Non-Executive Independent Director
• Elliott Sigal,
  Non-Executive Independent Director
• John Furey,
  Non-Executive Independent Director
• Barbara Duncan,
  Non-Executive Independent Director
• Ali Behbahani,
  Non-Executive Independent Director
• Lawrence Alleva,
  Non-Executive Independent Director
• John Lunger,
  Chief Patient Supply Officer
• Elliot Norry,
  Senior Vice President, Chief Medical Officer
• Gavin Wood,
  Chief Financial Officer
• Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Dr. Rafael G. Amado,
  Pres of R&D
• Sébastien Desprez,
  VP of Communications & Corp. Affairs
• Margaret Henry,
  Head of PR & Company Sec.
• Dr. Juli P. Miller Ph.D.,
  VP of Investor Relations
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Gwendolyn Knowlton Binder S...,
  EVP, Adaptimmune LLC
• Giles Francis Bertram Kerr,
  Director
• Jonathan Kenneth Charles Kn...,
  Director
• Forest Baskett,
  10% owner
• Ian Michael Laing,
  Director
• Rafael Amado,
  President, R&D
• Peter A. Thompson,
  Director
• Peter W. Sonsini,
  10% owner
• Patrick J Kerins,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 14, L...,
  
• Advisors Llc Orbi Med Capit...,
  
• Peter J Barris,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Kristen Hege,
  Director
• Priti Hegde,
  Director
• Andrew R Allen,
  Director
• Cintia Piccina,
  Chief Commercial Officer
• Joanna Elizabeth Brewer,
  Chief Scientific Officer
• Garry E Menzel,
  Director